Affymetrix to Webcast Presentation at JPMorgan Healthcare Conference
January 08 2009 - 4:00PM
Business Wire
Affymetrix Inc. (NASDAQ:AFFX) today announced that Kevin M. King,
president and chief executive officer, will provide a company
overview at the JPMorgan Healthcare Conference on January 15th in
San Francisco, CA. A live webcast of the presentation will take
place at 10:00 a.m. PT. To access both the live and archived
webcasts, please go to www.affymetrix.com and click on the
"Investors" link under the �Resources for� dropdown. An archived
webcast of the presentation will be available for 30 days. About
Affymetrix Affymetrix GeneChip� microarray technology is the
industry-standard tool for analyzing complex genetic information.
After inventing microarray technology in the late 1980s, Affymetrix
scientists have been dedicated to developing innovative products
that provide researchers with a more complete view of the genome.
These products continue to accelerate genetic research and enable
scientists to develop diagnostics and tailor treatments for
individual patients by identifying and measuring the genetic
information associated with complex diseases. Today, Affymetrix
technology is used by the world�s top pharmaceutical, diagnostic
and biotechnology companies, as well as leading academic,
government and not-for-profit research institutes. More than 1,800
systems have been shipped around the world and more than 14,000
peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Sacramento, Calif., Cleveland, Ohio,
and Singapore. The company has about 1,100 employees worldwide and
maintains sales and distribution operations across Europe and Asia.
For more information about Affymetrix, please visit the company�s
website at www.affymetrix.com. Forward-looking Statements All
statements in this press release that are not historical are
�forward-looking statements� within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix� �expectations,� �beliefs,� �hopes,�
�intentions,� �strategies� or the like. Such statements are subject
to risks and uncertainties that could cause actual results to
differ materially for Affymetrix from those projected, including,
but not limited to: risks and uncertainties relating to commercial
success of the agreement discussed in this press release; risks of
the company�s ability to achieve and sustain higher levels of
revenue, higher gross margins and reduced operating expenses;
uncertainties related to technological approaches, manufacturing
and product development; personnel retention; uncertainties related
to cost and pricing of Affymetrix products; dependence on
collaborative partners; uncertainties related to sole-source
suppliers; risks associated with past and future acquisitions;
uncertainties relating to FDA and other regulatory approvals;
competition; risks relating to intellectual property of others and
the uncertainties of patent protection and litigation. These and
other risk factors are discussed in Affymetrix� Form 10-K for the
year ended December 31, 2007, and other SEC reports, including its
Quarterly Reports on Form 10-Q for subsequent quarterly periods.
Affymetrix expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Affymetrix�
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip� are registered
trademarks owned or used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024